China Healthcare Weekly (Jan.15)
This article analyzed the new interim procedures released by NHSA, trend of blood products and biological drug market, and also include company...
382 Views
Man Wah Placement - Riding High on Planned Store Expansion
Man Wah Holdings (1999 HK) plans to raise around US$260m to expand manufacturing facilities in China and open new stores. The stock has nearly...
416 Views
Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed
Innovent Biologics Inc (1801 HK) is looking to raise about U$600m to fund its clinical trials and product licensing and possible M&A. This will be...
420 Views
BeiGene: Novartis Grabs Tislelizumab Rights
BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...
263 Views
BeiGene: Cancer Treatment in China--The Underestimated Opportunity
We think that cancer is underdiagnosed and undertreated in China. We analyze the data and propose two approaches for investing in this theme.
325 Views